Display options
Cite
Seoane S, Bermudez MA, Sendon-Lago J, et al. 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers (Basel). 2013;6(1):67-78doi: 10.3390/cancers6010067.
Seoane, S., Bermudez, M. A., Sendon-Lago, J., Martinez-Ordoñez, A., Abdul-Hadi, S., Maestro, M., Mouriño, A., & Perez-Fernandez, R. (2013). 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers, 6(1), 67-78. https://doi.org/10.3390/cancers6010067
Seoane, Samuel, et al. "26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines." Cancers vol. 6,1 (2013): 67-78. doi: https://doi.org/10.3390/cancers6010067
Seoane S, Bermudez MA, Sendon-Lago J, Martinez-Ordoñez A, Abdul-Hadi S, Maestro M, Mouriño A, Perez-Fernandez R. 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers (Basel). 2013 Dec 27;6(1):67-78. doi: 10.3390/cancers6010067. PMID: 24378752; PMCID: PMC3980618.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2013 Dec 27;6(1):67-78. doi: 10.3390/cancers6010067.

26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines.

Cancers

Samuel Seoane, Maria A Bermudez, Juan Sendon-Lago, Anxo Martinez-Ordoñez, Soraya Abdul-Hadi, Miguel Maestro, Antonio Mouriño, Roman Perez-Fernandez

Affiliations

  1. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  2. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  3. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  4. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  5. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  6. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  7. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].
  8. Department of Physiology-CIMUS, Endocrine Oncology Laboratories (P1L3), Avda. Barcelona s/n, Campus Vida-University of Santiago de Compostela, Santiago de Compostela 15782, Spain. [email protected].

PMID: 24378752 PMCID: PMC3980618 DOI: 10.3390/cancers6010067

Abstract

It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In the present study using human breast cancer cell lines, the biological activity of 1,25D-d6 administered alone and in combination with two commonly used antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both compounds. Interestingly, the antitumoral effect is higher in the more aggressive MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone or in combination with chemotherapy could be a good experimental method for accurately quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast cancer cell lines and in vivo animal experimental models.

References

  1. J Bone Miner Res. 1988 Feb;3(1):87-91 - PubMed
  2. Mol Cell Endocrinol. 1998 Jul 25;142(1-2):57-65 - PubMed
  3. Anticancer Res. 2006 Jul-Aug;26(4A):2573-80 - PubMed
  4. Clin Cancer Res. 2005 Nov 1;11(21):7794-9 - PubMed
  5. Cancer Res. 2000 Apr 1;60(7):2040-8 - PubMed
  6. J Steroid Biochem Mol Biol. 1996 Jul;58(4):367-76 - PubMed
  7. Breast Cancer Res Treat. 1994;31(2-3):191-202 - PubMed
  8. Cancer. 2001 Jun 15;91(12):2431-9 - PubMed
  9. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26 - PubMed
  10. Cancer Chemother Pharmacol. 2007 Apr;59(5):581-7 - PubMed
  11. Cancer Res. 1991 Jun 1;51(11):2848-53 - PubMed
  12. Clin Pharmacol Ther. 2002 Dec;72(6):648-59 - PubMed
  13. Cancer J. 2010 Jan-Feb;16(1):1-9 - PubMed
  14. BMC Cancer. 2010 Sep 11;10:483 - PubMed
  15. Biochem Cell Biol. 1994 Nov-Dec;72(11-12):537-45 - PubMed
  16. Clin Biochem. 2013 Sep;46(13-14):1264-71 - PubMed
  17. Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):6-11 - PubMed
  18. Int J Cancer. 2003 Aug 20;106(2):178-86 - PubMed
  19. Clin Chim Acta. 2011 Aug 17;412(17-18):1594-9 - PubMed
  20. Oncogene. 1997 Sep 25;15(13):1555-63 - PubMed
  21. Oncogene. 1994 Dec;9(12):3407-15 - PubMed
  22. Apoptosis. 2010 Feb;15(2):162-72 - PubMed
  23. Nat Rev Cancer. 2007 Sep;7(9):684-700 - PubMed
  24. J Biol Chem. 2001 Mar 23;276(12):9101-7 - PubMed
  25. Carcinogenesis. 2007 May;28(5):1000-7 - PubMed
  26. Clin Cancer Res. 2007 Feb 15;13(4):1216-23 - PubMed
  27. J Med Chem. 2013 May 23;56(10):3878-88 - PubMed
  28. Breast Cancer Res Treat. 1999 Jan;53(2):113-20 - PubMed
  29. Clin Cancer Res. 1999 Jun;5(6):1339-45 - PubMed
  30. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1427-37 - PubMed
  31. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 - PubMed
  32. J Clin Invest. 2010 Dec;120(12):4289-302 - PubMed
  33. Differentiation. 2007 Mar;75(3):193-207 - PubMed
  34. Anticancer Res. 2004 Sep-Oct;24(5A):2905-12 - PubMed
  35. Cancer Res. 1999 Feb 15;59(4):862-7 - PubMed
  36. Cancer Res. 1990 Nov 1;50(21):6857-64 - PubMed

Publication Types